このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Carasent 配当金

配当金基準チェック /26

Carasent配当を支払う会社であり、現在の利回りは9.79%です。

主要情報

9.7%

配当利回り

-243%

配当性向

業界平均利回り	1.6%
次回配当支払日	n/a
配当落ち日	n/a
一株当たり配当金	n/a
一株当たり利益	-kr0.77
3年後の配当利回り予想	0%

最近の配当金アップデート

Recent updates

Carasent ASA's (OB:CARA) Intrinsic Value Is Potentially 73% Above Its Share Price

May 11

Is Carasent ASA (OB:CARA) Potentially Undervalued?

Mar 18

Is Now The Time To Look At Buying Carasent ASA (OB:CARA)?

Nov 22

Carasent's (OB:CARA) Solid Profits Have Weak Fundamentals

May 06

Returns Are Gaining Momentum At Carasent (OB:CARA)

Apr 29

Carasent ASA Beat Analyst Profit Forecasts, And Analysts Have New Estimates

Feb 13

There Are Reasons To Feel Uneasy About Carasent's (OB:CARA) Returns On Capital

Nov 24

Calculating The Intrinsic Value Of Carasent ASA (OB:CARA)

May 23

We Like These Underlying Trends At Carasent (OB:CARA)

Feb 28

What Type Of Shareholders Own The Most Number of Carasent ASA (OB:CARA) Shares?

Jan 24

決済の安定と成長

配当データの取得

安定した配当: CARAは 10 年未満配当金を支払っており、この間、支払額は変動性が高かった。

増加する配当: CARAの配当金は増加していますが、同社は6年間しか配当金を支払っていません。

配当利回り対市場

Carasent 配当利回り対市場

CARA 配当利回りは市場と比べてどうか？
セグメント	配当利回り
会社 (CARA)	9.7%
市場下位25% (NO)	3.5%
市場トップ25% (NO)	8.0%
業界平均 (Healthcare Services)	1.6%
3年後のアナリスト予想 (CARA)	0%

注目すべき配当: CARAの配当金 ( 9.79% ) はNorwegian市場の配当金支払者の下位 25% ( 3.44% ) よりも高くなっています。

高配当: CARAの配当金 ( 9.79% ) はNorwegian市場 ( 7.81% ) の配当支払者の中で上位 25% に入っています。

株主への利益配当

収益カバレッジ: CARAは配当金を支払っていますが、会社は利益を上げていません。

株主配当金

キャッシュフローカバレッジ: CARAは配当金を支払っていますが、同社にはフリーキャッシュフローがありません。

Carasent 配当金

配当金 基準チェック /26

主要情報

最近の配当金アップデート

Carasent Asa Approves Dividend

Upcoming dividend of kr1.84 per share

Recent updates

Eg Norge A/S contemplates launching a voluntary cash offer to acquire Carasent ASA (OB:CARA) for NOK 1.4 billion.

Eg Norge A/S contemplates launching a voluntary cash offer to acquire Carasent ASA (OB:CARA) for NOK 1.4 billion.

First quarter 2024 earnings released: kr0.15 loss per share (vs kr0.01 loss in 1Q 2023)

Carasent ASA's (OB:CARA) 32% Jump Shows Its Popularity With Investors

New major risk - Share price stability

Carasent ASA Announces Changes to Its Board

Full year 2023 earnings: EPS exceeds analyst expectations

Chief Executive Officer recently bought kr1.4m worth of stock

Independent Director recently bought kr100k worth of stock

Full year 2023 earnings: EPS exceeds analyst expectations

Founder recently bought kr28m worth of stock

High number of new and inexperienced directors

Calculating The Fair Value Of Carasent ASA (OB:CARA)

Carasent ASA Announces Staffan Hanstorp Resigns as A Member of the Board of Directors

Carasent ASA to Report Fiscal Year 2023 Results on Mar 22, 2024

Chief Financial Officer recently bought kr165k worth of stock

Is It Too Late To Consider Buying Carasent ASA (OB:CARA)?

New minor risk - Share price stability

Carasent Asa Approves Dividend

Independent Director recently bought kr111k worth of stock

Upcoming dividend of kr1.84 per share

Price target decreased by 9.4% to kr29.00

Chief Executive Officer recently bought kr96k worth of stock

Carasent's (OB:CARA) Returns On Capital Are Heading Higher

Chief Executive Officer recently bought kr97k worth of stock

Second quarter 2023 earnings: EPS misses analyst expectations

Consensus EPS estimates upgraded to kr0.53 loss

Carasent ASA's (OB:CARA) Intrinsic Value Is Potentially 73% Above Its Share Price

Price target decreased by 12% to kr33.50

First quarter 2023 earnings released: kr0.01 loss per share (vs kr0.32 profit in 1Q 2022)

Is Carasent ASA (OB:CARA) Potentially Undervalued?

Full year 2022 earnings released: EPS: kr0.39 (vs kr0.002 loss in FY 2021)

Price target decreased by 8.6% to kr37.00

Carasent ASA to Report Q1, 2023 Results on May 04, 2023

Is Now The Time To Look At Buying Carasent ASA (OB:CARA)?

High number of new and inexperienced directors

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Consensus forecasts updated

Price target decreased to kr40.50

Carasent ASA (OB:CARA) acquired HPI Health Profile Institute AB for SEK 35 million.

Carasent ASA Provides Earnings Guidance for the Third Quarter and Full Year 2022

Carasent Asa Announces That Johan Lindqvist to Step Down as Chairman of the Board

Price target decreased to kr44.50

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Investor sentiment improved over the past week

Price target decreased to kr46.50

Investor sentiment improved over the past week

Consensus forecasts updated

Price target decreased to kr48.50

Carasent's (OB:CARA) Solid Profits Have Weak Fundamentals

First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Returns Are Gaining Momentum At Carasent (OB:CARA)

Dennis Höjer Informs that He Will Step Down as CEO of Carasent ASA

No independent directors

Full year 2021 earnings: EPS misses analyst expectations

Carasent ASA Beat Analyst Profit Forecasts, And Analysts Have New Estimates

Full year 2021 earnings: EPS misses analyst expectations

Price target decreased to kr54.00

Carasent ASA (OB:CARA) completed the acquisition of Medrave Software AB.

Carasent ASA (OB:CARA) agreed to acquire Medrave Software AB for approximately SEK 130 million.

There Are Reasons To Feel Uneasy About Carasent's (OB:CARA) Returns On Capital

Price target increased to kr61.00

Third quarter 2021 earnings released: kr0.28 loss per share (vs kr0.21 loss in 3Q 2020)

Second quarter 2021 earnings released: EPS kr0.34 (vs kr0.14 loss in 2Q 2020)

Chief Financial Officer Lars Forsberg has left the company

Carasent ASA announced that it has received NOK 420.155987 million in funding from Cardigan Holdco S.à r.l.

Carasent ASA (OB:CARA) acquired Metodika AB for approximately SEK 110 million.

Calculating The Intrinsic Value Of Carasent ASA (OB:CARA)

First quarter 2021 earnings released: kr0.14 loss per share (vs kr0.01 profit in 1Q 2020)

Full year 2020 earnings released: kr0.85 loss per share (vs kr0.079 profit in FY 2019)

Aeternum Capital AS, a fund managed by Aeternum Management AS acquired 15% stake in Carasent ASA (OB:CARA).

We Like These Underlying Trends At Carasent (OB:CARA)

Revenue and earnings miss expectations

配当金基準チェック /26